Company Overview and News
KUALA LUMPUR (Oct 16): The FBM KLCI started off on a muted note this morning against teh backdrop of modest gains at regional markets, as key index-linked heavyweights dragged.
5183 MLYBY PECGF MLYNF BATS 4162 5246 7022 9059 CIMDF GBTKF 1155 1023
China is unlikely to let the yuan weaken past the key psychological level of 7 per dollar any time soon, according to market observers.
UOVEF STAN MLYBY MLYNF U11 1155 3968 580001 STAB STAN STAC 2888 SCBFF UOVEY
KUALA LUMPUR (Oct 15): Malayan Banking Bhd is expected to face a challenging second half this year (2H18), given the risk of potentially higher levels of provisions, elevated funding costs and modest loan growth, according to Affin Hwang Capital Research.
1155 MLYBY MLYNF
KUALA LUMPUR (Oct 15): The FBM KLCI rose 0.24% at mid-morning today, defending its level above the 1,730-point level, lifted by gains at select blue chips.
HLFBF 7293 BRDBF MLYNF 7113 TPGVF 2089 5199 5210 3026 2836 HIPEF GEBHF HRGHY 5183 MLYBY PECGF UPBMF 1082 5681 5168 TGLVY 5436 5238 1155 0047
KUALA LUMPUR (Oct 12): The FBM KLCI rose 0.79% in a technical rebound at the midday break today, snapping its seven-day losing streak, lifted by index heavyweights including Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd (TNB).
HLFBF MLYBY MLYNF 7036 1082 7006 5135 6033 5199 CIMDF 1155 KLKBY 1023 2445 PNADF 5347 TNABY 6888 0006 5819 AXXTF TNABF HIPEF PNAGF
KUALA LUMPUR (Oct 12): The FBM KLCI staged a technical rebound today to snap its losing streak and rose 0.54% at mid-morning, reversing its earlier loss, lifted by index heavyweights Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd.
MLYBY MLYNF UPBMF 7036 BATS 4162 3034 2089 5014 9334 5199 2852 1155 5347 3301 3867 TNABY MYPRY 2836 TNABF HIPEF GEBHF
KUALA LUMPUR, Oct 9 — Standard & Poor’s Rating Services is upbeat of Malaysia’s prospects and a rating upgrade is possible if the country can improve total revenue to gross domestic product (GDP) ratio.
1155 1023 MLYBY MLYNF CIMDF
SINGAPORE (Oct 5): Singapore water treatment firm Hyflux Ltd, which is undergoing a court-supervised reorganisation, said on Friday it was actively engaged in discussions with potential investors for its Tuaspring project or the rest of the group, or both.
1155 MLYBY MLYNF HYFXF U96 HYFXY SCRPF SCRPY
KUALA LUMPUR (Oct 4): Based on corporate announcements and news flow today, companies that may be in focus on Friday (Oct 5) may include the following: Malayan Banking Bhd, Aeon Credit Service (M) Bhd, Nestle (Malaysia) Bhd, Press Metal Aluminium Holdings Bhd, Alcom Group Bhd, Eonmetall Group Bhd, FGV Holdings Bhd and DBE Gurney Resources Bhd.
1155 5139 MLYBY 7217 0900 8869 MLYNF NSLYF BSMAF 1818
KUALA LUMPUR (Oct 4): Malayan Banking Bhd (Maybank) has obtained approval from the Monetary Authority of Singapore (MAS) to locally incorporate its Community Financial Services (CFS) business in Singapore.
1155 MLYBY MLYNF
Aspial: Aspial Corp is launching S$20.75 million in additional notes under its S$700 million multi-currency debt issuance programme at a coupon of 6.25 per cent following interest from its investors. The notes, which are due 2021, add to an earlier tranche of S$29.25 million in notes, taking the total under the Series 006 notes that will be issued to S$50 million. The Series 006 notes are expected to be issued on Oct 11, and will be used to finance the general funding requirements or investments of the group, for working capital and for capital expenditure.
TXN MLYBY MLYNF U96 HYFXY S69 SCRPY 1155 M35 H07 HYFXF SCRPF SMFOY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...